IP Library › Granted Patent US 12,357,654
Granted Patent B2
US 12,357,654 · App. 17/618,311 · Granted Jul 15, 2025

Application of glucan in preparation of drug

Inventors: Jinbo Yang (Shandong, CN); Guangli Yu (Shandong, CN); Qiaoling Song (Shandong, CN); Lijuan Wu (Shandong, CN); Jun Zhao (Shandong, CN); Youjing Lv (Shandong, CN); Chenyang Zhao (Shandong, CN); Huashi Guan (Shandong, CN)
Assignees: QINGDAO CONSON PHARMACEUTICAL CO., LTD.; MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD.
A61K31/716A61K45/06A61P7/00A61P35/00A61P37/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,357,654
App. No.
17/618,311
Granted
Jul 15, 2025
Kind
B2
Abstract

An application of a glucan in the preparation of a drug. A β-1,3/1,6-glucan is used for preparing a pharmaceutical composition or formulation. The pharmaceutical composition or formulation can enhance the antitumor effect of immunotherapy, radiotherapy, or chemotherapy, and is used for treating leukopenia and/or thrombocytopenia.

Claims (14)

1. A method for treating leukopenia and/or thrombocytopenia, the method comprising a step of administering β-1,3/1,6-glucan in combination with an immune checkpoint drug to a subject in need, wherein the β-1,3/1,6-glucan is derived from Antarctic brown algae; wherein the immune checkpoint drug is a programmed death 1 protein (PD-1) antagonist or a PD-L1 antagonist.

2. The method according to claim 1 , wherein the immune checkpoint drug is selected from the group consisting of an anti-PD-1 antibody and an anti-PD-L1 antibody.

3. The method according to claim 2 , wherein the anti-PD-1 antibody or PD-L1 antibody is selected from Durvalumab, Atezolizumab, Nivolumab, Spartalizumab, and Camrelizumab, or a combination thereof.

4. The method according to claim 1 , wherein the β-1,3/1,6-glucan is can further be administered in combination with at least one chemotherapeutic agent.

5. The method according to claim 4 , wherein the at least one chemotherapeutic agent is selected from cytotoxic chemotherapeutic agents.

6. The method according to claim 1 , wherein the β-1,3/1,6-glucan is further administered in combination with radiotherapy.

7. The method according to claim 1 , wherein the subject in need is a subject with cancer.

8. The method according to claim 7 , wherein the cancer is selected from one or more of melanoma, colorectal cancer, lung cancer, kidney cancer, liver cancer and breast cancer.

9. The method according to claim 1 , wherein the Antarctic brown algae is selected from Cochayuyo, sea bamboo shoot, Lessonia trabeculata , or Durvillaea antarctica.

10. The method according to claim 1 , wherein the Antarctic brown algae is Durvillaea antarctica.

11. The method according to claim 1 , wherein the β-1,3/1,6-glucan is a β-glucan of formula (I) and/or formula (II),

wherein n is an integer selected from 1-20, and R is H and/or no more than 4 glucose residues.

12. The method according to claim 1 , wherein the β-1,3/1,6-glucan has a molecular weight of 1-50 kDa.

13. The method according to claim 1 , wherein the thrombocytopenia is a thrombocytopenia caused by the use of the immune checkpoint drug.

Assignments (2)
CHANGE OF NAME Recorded Apr 3, 2025
From: CP PHARMACEUTICAL QINGDAO CO., LTD.
To: QINGDAO CONSON PHARMACEUTICAL CO., LTD.
Reel/Frame 070734/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2021
From: YANG, JINBO; YU, GUANGLI; SONG, QIAOLING; WU, LIJUAN; ZHAO, JUN; LV, YOUJING; ZHAO, CHENYANG; GUAN, HUASHI
To: CP PHARMACEUTICAL QINGDAO CO., LTD.; MARINE BIOMEDICAL RESEARCH INSTITUTE OF QINGDAO CO., LTD.
Reel/Frame 058370/0755 →
Priority Claims (1)
CN 201910512814.6 · Jun 13, 2019 · national
Continuity (1)
Related Publication 20220331352A1 · Oct 20, 2022
References Cited (29)
US 10912794B2 · Horst et al. · 2021 [cited by applicant]
CN 101020719A · 2007 [cited by applicant]
CN 105001352A · 2015 [cited by applicant]
CN 108430479A · 2018 [cited by applicant]
CN 109793752A · 2019 [cited by applicant]
JP H8500623A · 1996 [cited by applicant]
JP 2017535543A · 2017 [cited by applicant]
WO 9404163A1 · 1994 [cited by applicant]
WO 2004014320A2 · 2004 [cited by applicant]
WO 2016073763A2 · 2016 [cited by applicant]
Orecchioni et al. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma (BJC, 2018,… [cited by examiner]
Bobadilla et al., “Soluble Beta-1,3/1,6-glucan in seaweed from the southern hemisphere and its immunomodulatory effect,” Carbohydrate Polymers, vol. 92, pp. 241-248 (2013). [cited by applicant]
Camilli et al., “The Complexity of Fungal beta-Glucan in Health and Disease: Effects on the Mononuclear Phagocyte System,” Front Immunol., vol. 9, No. 673, pp. 1-9 (2018). [cited by applicant]
Kim et al., “Immune escape tp PD-L1/PD-1 blockade: seven steps to success,” Annals of Oncology, vol. 27, pp. 1492-1504 (2016). [cited by applicant]
Mahoney et al., “Combination cancer immunotherapy and new immunomodulatory targets,” Nat. Rev. Drug Discov., vol. 14, No. 8, pp. 561-584 (2015). [cited by applicant]
Wang et al., “Structural characterization and immuno-enhancing activity of a highly branched water-soluble beta-glucan from the spores of Ganoderma lucidum,” Carbohydrate Polymers, vol. 167, pp. 337-344 (2017). [cited by applicant]
Wu et al., “Advances in the study of immunomodulatory effects of beta-glucan,” Chin. J. Cell Mol. Immunol., vol. 30, No. 1, pp. 97-100 (2014) (with machine English translation of Abstract). [cited by applicant]
Zhang et al., “Optimizing Tumor Microenvironment for Cancer Immunotherapy: Beta-Glucan-Based Nanoparticles,” Frontiers in Immunolgy, vol. 9, No. 341, pp. 1-14 (2018). [cited by applicant]
Office Action issued Jan. 4, 2023 in JP Application No. 2021574203 (English translation). [cited by applicant]
Office Action issued Jan. 13, 2023 in CA Application No. 3143308. [cited by applicant]
Extended European Search Report issued Jun. 9, 2023 in EP Application No. 20822937.7. [cited by applicant]
Office Action issued Dec. 12, 2022 in AU Application No. 2020291757. [cited by applicant]
Office Action issued Jul. 28, 2022 in CN Application No. 202080043041.2 (English translation). [cited by applicant]
Office Action issued Feb. 22, 2023 in CN Application No. 202080043041.2. [cited by applicant]
Karaca et al., “Positive Effects of Oral b-Glucan on Mucositis and Leukopenia in Colorectal Cancer Patients Receiving Adjuvant Folfox-4 Combination Chemotherapy,” Asian Pacific Journal of Cancer Prevention, vol. 15, No.… [cited by applicant]
Ghareeb et al., “Concomitant treatment with beta-glucan and G-CSF ameliorates altered biochemical indices after cyclophosphamide-induced leukopenia in mice,” Biotechnology & Biotechnological Equipment, vol. 29, No. 5., … [cited by applicant]
Su et al., “A b-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator,” Carbohydrate Polymers, vol. 222, 114993, pp. 1-11 (2019). [cited by applicant]
Chae et al., “Yeast (1-3)-(1-6)-b-D-glucan alleviates immunosuppression in gemcitabine-treated mice,” International Journal of Biological Macromolecules, vol. 136, pp. 1169-1175 (2019). [cited by applicant]
Yang et al., “A b-glucan from Durvillaea Antarctica has immunomodulatory effects on RAW264.7 macrophages via toll-like receptor 4,” Carbohydrate Polymers, vol. 191, pp. 255-265 (2018). [cited by applicant]